Northern Trust Corp Gain Therapeutics, Inc. Transaction History
Northern Trust Corp
- $586 Billion
- Q2 2024
A detailed history of Northern Trust Corp transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 44,944 shares of GANX stock, worth $79,550. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44,944
Previous 46,486
3.32%
Holding current value
$79,550
Previous $175,000
67.43%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding GANX
# of Institutions
31Shares Held
3.75MCall Options Held
0Put Options Held
0-
Timelo Investment Management Inc.605KShares$1.07 Million0.45% of portfolio
-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.04 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1 Million0.04% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL450KShares$796,5000.0% of portfolio
-
Hohimer Wealth Management, LLC330KShares$584,1000.1% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $21M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...